About Femeda
Femeda is a company based in York (United Kingdom) founded in 2003. Femeda has raised $7.74 million across 3 funding rounds from investors including Mercia, Enterprise Ventures and Northstar Ventures. The company has 12 employees as of December 31, 2020. Femeda offers products and services including Pelviva. Femeda operates in a competitive market with competitors including Axonics, Laborie Medical, Amber Therapeutics, NeuSpera Medical and UroMems, among others.
- Headquarter York, United Kingdom
- Employees 12 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Femeda Limited
- Date of Incorporation 08 Nov, 2002
- Jurisdiction CRAMLINGTON, ENGLAND
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$7.74 M (USD)
in 3 rounds
-
Latest Funding Round
$5.17 M (USD), Series A
Feb 11, 2019
-
Investors
Mercia
& 4 more
-
Employee Count
12
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Femeda
Femeda offers a comprehensive portfolio of products and services, including Pelviva.
Device for retraining pelvic floor muscles to improve bladder control.
People of Femeda
Unlock access to complete
Unlock access to complete
Funding Insights of Femeda
Femeda has successfully raised a total of $7.74M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $5.17 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $5.2M
-
First Round
First Round
(23 Apr 2007)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2019 | Amount | Series A - Femeda | Valuation | Mercia |
|
| Oct, 2015 | Amount | Series A - Femeda | Valuation |
investors |
|
| Apr, 2007 | Amount | Seed - Femeda | Valuation | Northstar Ventures , Stargate Capital |
Investors in Femeda
Femeda has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Mercia, Enterprise Ventures and Northstar Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early and Growth stage Venture Debt firm that does debt investments in the UK
|
Founded Year | Domain | Location | |
|
Early-stage investments are made in UK companies across diverse sectors.
|
Founded Year | Domain | Location | |
|
Investment management services are provided by Mercia to various clients.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Femeda
Financial Statements - Femeda
Femeda Comparisons
Competitors of Femeda
Femeda operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Axonics, Laborie Medical, Amber Therapeutics, NeuSpera Medical and UroMems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Sacral neuromodulation devices are developed for urinary and bowel control.
|
|
| domain | founded_year | HQ Location |
Medical products for female lower urinary tract dysfunctions are provided.
|
|
| domain | founded_year | HQ Location |
Bioelectrical therapies for peripheral nervous system disorders are developed.
|
|
| domain | founded_year | HQ Location |
Miniaturized injectable neuromodulation devices are developed for chronic diseases.
|
|
| domain | founded_year | HQ Location |
Developer of active implantable devices for urological incontinence
|
|
| domain | founded_year | HQ Location |
Non-invasive wearable devices for pelvic floor strengthening are developed.
|
Frequently Asked Questions about Femeda
Femeda was founded in 2003 and raised its 1st funding round 4 years after it was founded.
Femeda is headquartered in York, United Kingdom.
Andrew Tasker is the current CEO of Femeda.
Femeda is a funded company, having raised a total of $7.74M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.56M, raised on Apr 23, 2007.
As of Dec 31, 2020, the latest employee count at Femeda is 12.
Founded in 2003 and based in York, United Kingdom, a disposable medical device for urinary incontinence treatment is developed. The device, shaped like a tampon, is inserted vaginally via a plastic applicator to stimulate pelvic floor muscles electrically. It operates for 30 minutes before automatic shutdown and is then discarded. Operations focus on this single-use product within the womens health sector.
Femeda's top competitors include Axonics, NeuSpera Medical and Laborie Medical.
Femeda offers Pelviva.
Femeda has 5 investors. Key investors include Mercia, Enterprise Ventures, Northstar Ventures, Stargate Capital, and Acceleris Capital.